ランキングに戻る

BGM Group Ltd. (BGM)

割安
HealthcareDrug Manufacturers - Specialty & GenericChina

ファンダメンタル

32

株価

$0.25

時価総額

$100M

パート1 · 企業の価値

概要

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

Jinhe Biotechnology Co., Ltd. (金河生物科技股份有限公司)002688.SZ

Both are Chinese producers of tetracycline-class antibiotic active ingredients and premixes sold to the same livestock, poultry and feed customers at home and for export.

Ningxia Tairui Pharmaceutical Co., Ltd. (宁夏泰瑞制药股份有限公司)Not tracked

A non-listed Chinese maker of non-sterile veterinary antibiotic active ingredients and feed additives, selling into the same animal-health raw-material market as BGM's oxytetracycline business.

Wuhan Hvsen Biotechnology Co., Ltd. (武汉回盛生物科技股份有限公司)300871.SZ

Makes veterinary antibiotic active ingredients and the finished animal medicines built on them, competing for the large Chinese pig, poultry and aquaculture producers that also buy BGM's products.

China Animal Husbandry Industry Co., Ltd. (中牧实业股份有限公司)600195.SS

A long-established state-backed supplier of veterinary drugs and veterinary active ingredients to Chinese farms, overlapping with BGM on the animal-medicine side of its pharmaceutical segment.

貸借対照表と流動性

売上高

$39M

直近の公表四半期までの12か月 — 1株当たり指標からの推計

純利益

$-25M

直近の公表四半期までの12か月 — 1株当たり指標からの推計

フリーキャッシュフロー

$-5M

自己資本合計

$391M

負債合計

$42M

流動比率

1.24

利払い倍率

-

負債/EBITDA

-

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割安

適正価値

$0.49

現在株価

$0.25

安全マージン

+49.0%

適正価値レンジ

$0.47 - $0.52

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:算出に必要なデータが不足しています
ディスカウンテッド・キャッシュフロー(DCF):$0.49
利益倍率(P/E):算出に必要なデータが不足しています
グレアムの成長公式:算出に必要なデータが不足しています
収益力価値(EPV):算出に必要なデータが不足しています
正当化されたP/B:算出に必要なデータが不足しています
配当割引モデル(ゴードン):算出に必要なデータが不足しています
P/FFO(運用から生まれる資金):算出に必要なデータが不足しています
中間サイクル利益:算出に必要なデータが不足しています
売上高倍率:$0.77

バリュエーション指標

P/E レシオ

-

ROE

-5.1%

P/B レシオ

0.13

P/FCF

-

粗利益率

16.6%

ROIC

-2.5%

収益性レーダー

価値創造(経済的モート)

ROIC

-2.5%

WACC

15.0%

ROIC − WACC

-17.5 pp

ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。

ファンダメンタル分析基準

合格(4)

  • P/B Ratio 0.13
  • Debt/Equity ratio
  • Current Ratio
  • DCF valuation (Undervalued)

不合格(11)

  • EPS shows upward trend
  • Price CAGR -54.62%
  • ROIC -2.5%
  • Gross Margin 16.6%
  • Operating Margin -33.2%
  • Positive Free Cash Flow
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Share Dilution 1435.7%
  • Net Margin Trend -52.6% vs -5.7%
  • Piotroski F-Score 3/9

データなし(12)

  • P/FCF NaN
  • Dividend Payout NaN%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-スコア

3/9

重大な財務上の懸念

score
criteria

利益の質

-

低品質:会計処理を調査してください

株式希薄化

1435.7%

新株を発行しており、所有権を希薄化している

機関投資家の保有

この企業について機関投資家の報告はありません。

ガバナンス

経営陣

氏名役職年齢
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.